N/A
Manufactured by Domp farmaceutici S.p.A.
28,659 FDA adverse event reports analyzed
Last updated: 2026-04-14
CENEGERMIN BKBJ is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Domp farmaceutici S.p.A.. The most commonly reported adverse reactions for CENEGERMIN BKBJ include EYE PAIN, EYE IRRITATION, PRODUCT DOSE OMISSION ISSUE, OCULAR HYPERAEMIA, PHOTOPHOBIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CENEGERMIN BKBJ.
Out of 11,957 classified reports for CENEGERMIN BKBJ:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 28,659 FDA FAERS reports that mention CENEGERMIN BKBJ. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include EYE PAIN, EYE IRRITATION, PRODUCT DOSE OMISSION ISSUE, OCULAR HYPERAEMIA, PHOTOPHOBIA, VISION BLURRED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Domp farmaceutici S.p.A. in connection with CENEGERMIN BKBJ. Always verify the specific product and NDC with your pharmacist.